Description

Bonesupport Holding AB (publ) operates as a prominent orthobiologics firm, dedicated to the development and worldwide commercialization of injectable bioceramic bone graft alternatives. These solutions are utilized for filling bone voids across international markets, specifically targeting regions such as Europe and North America. The company's primary product line features CERAMENT Bone Void Filler, a synthetic material designed for injection, which is both moldable and drillable. Its composition includes hydroxyapatite, calcium sulfate, and the radio-contrast agent iohexol. Other key offerings are CERAMENT G, an injectable ceramic bone graft substitute infused with gentamicin, and CERAMENT V, a synthetic injectable bone void filler fortified with vancomycin. Beyond its commercialized products, Bonesupport actively pursues preclinical development, focusing on pioneering new solutions to stimulate bone regrowth. These research efforts address complex medical challenges such as trauma, revision arthroplasty, chronic osteomyelitis, oncology-related bone issues, and diabetic bone and foot infections. Established in 1999, the company's corporate headquarters are situated in Lund, Sweden.